A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer

Trial Profile

A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Dasatinib (Primary) ; Gonadotropin releasing hormone stimulants
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Apr 2013 New trial record
    • 01 Apr 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top